Cart
sales@molnova.com
Benzododecinium chloride
CAS No. 139-07-1
Benzododecinium chloride( Lauralkonium chloride,NSC 85508,NSC85508 )
Catalog No. M22959 CAS No. 139-07-1
Benzyldimethyldodecylammonium chloride is a quaternary ammonium compound.Benzododecinium chloride is an irritant for eye.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 37 | In Stock |
|
| 500MG | 59 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBenzododecinium chloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionBenzyldimethyldodecylammonium chloride is a quaternary ammonium compound.Benzododecinium chloride is an irritant for eye.
-
DescriptionBenzyldimethyldodecylammonium chloride is a quaternary ammonium compound.Benzododecinium chloride is an irritant for eye.
-
In Vitro——
-
In Vivo——
-
SynonymsLauralkonium chloride,NSC 85508,NSC85508
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number139-07-1
-
Formula Weight339.99
-
Molecular FormulaC21H38ClN
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble
-
SMILESC[N+](CCCCCCCCCCCC)(CC1=CC=CC=C1)C.[Cl-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ferreira C, Pereira AM, Pereira MC, Melo LF, Sim?es M. Physiological changes induced by the quaternary ammonium compound benzyldimethyldodecylammonium chloride on Pseudomonas fluorescens. J Antimicrob Chemother. 2011 May;66(5):1036-43. doi: 10.1093/jac/dkr028. Epub 2011 Feb 8. PubMed PMID: 21393196.
molnova catalog
related products
-
62'-Dihydroxyflavone
62'-Dihydroxyflavone is a novel antagonist of GABAA receptor.
-
Sodium Hydrogen Sulf...
Sodium Hydrogen Sulfide (hydrate) is, like nitric oxide, an important gaseous mediator that has significant effects on the immunological, neurological, cardiovascular and pulmonary systems of mammals.
-
TT-10
TT-10 (TAZ-K), an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity, has potential application in heart disease research, specifically for conditions characterized by loss of cardiomyocytes.
